Pages that link to "Q28199030"
Jump to navigation
Jump to search
The following pages link to Aspirin resistance: definition, mechanisms and clinical read-outs (Q28199030):
Displaying 50 items.
- Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis (Q24645413) (← links)
- The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? (Q24794673) (← links)
- Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease (Q27027247) (← links)
- (Q28164962) (redirect page) (← links)
- Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes (Q28165235) (← links)
- Aspirin resistance (Q28167475) (← links)
- A critical appraisal of the phenomenon of aspirin resistance (Q28183919) (← links)
- Determinants of the interindividual variability in response to antiplatelet drugs (Q28187591) (← links)
- Aspirin resistance (Q28187611) (← links)
- Resistance to antiplatelet drugs: current status and future research (Q28192298) (← links)
- Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial (Q28193982) (← links)
- Aspirin and clopidogrel resistance: an emerging clinical entity (Q28194021) (← links)
- More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm (Q28194568) (← links)
- Aspirin resistance (Q28195157) (← links)
- Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease (Q28196932) (← links)
- Response to aspirin and clopidogrel monitored with different platelet function methods (Q28200256) (← links)
- Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables (Q28200267) (← links)
- Current developments in anti-platelet therapy (Q28200685) (← links)
- Aspirin resistance: a revival of platelet aggregation tests? (Q28208759) (← links)
- Aspirin resistance in vitro and hypertension in stroke patients (Q28210375) (← links)
- More on: aspirin resistance (Q28210563) (← links)
- Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease (Q28211198) (← links)
- Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design (Q28211902) (← links)
- Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions (Q28211940) (← links)
- Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain (Q28212771) (← links)
- Drug insight: aspirin resistance--fact or fashion? (Q28213070) (← links)
- Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions (Q28213402) (← links)
- Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin (Q28217950) (← links)
- The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy (Q28220382) (← links)
- Platelet function testing: state of the art (Q28221566) (← links)
- Clinical implications of aspirin resistance (Q28221576) (← links)
- Module-based association analysis for omics data with network structure (Q30919427) (← links)
- Role of TGF-beta1 and MAP kinases in the antiproliferative effect of aspirin in human vascular smooth muscle cells (Q33546380) (← links)
- Critical Overview on the Benefits and Harms of Aspirin. (Q33664298) (← links)
- Acetylsalicylic acid enhances purinergic receptor-mediated outward currents in rat megakaryocytes (Q33727708) (← links)
- Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention (Q33810226) (← links)
- Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. (Q34433987) (← links)
- Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance (Q34771381) (← links)
- Effects of Aspirin Responsiveness and Platelet Reactivity on Early Vein Graft Thrombosis After Coronary Artery Bypass Graft Surgery (Q34952522) (← links)
- Intracellular Erythrocyte Platelet-activating Factor Acetylhydrolase I Inactivates Aspirin in Blood (Q35266471) (← links)
- The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA. (Q35395358) (← links)
- Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis (Q36010925) (← links)
- Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? (Q36266049) (← links)
- Antiplatelet drug resistance: not ready for prime time (Q36289432) (← links)
- Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients (Q36881941) (← links)
- Aspirin resistance: biological and clinical implications (Q37089560) (← links)
- Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease (Q37248584) (← links)
- Aspirin resistance: an update (Q37396572) (← links)
- Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). (Q37765146) (← links)
- Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors (Q37893966) (← links)